Skip to menu Skip to content Skip to footer

2024

Journal Article

Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study

Bestgen, Benoit, Jones, Sam, Thathy, Vandana, Kuemmerle, Andrea, Barcelo, Catalina, Haouala, Amina, Gossen, Denis, Marx, Michael W, Di Resta, Ilaria, Szramowska, Maja, Webster, Rebecca A, Llewellyn, Stacey, Ritacco, Dominic A, Yeo, Tomas, Leroy, Didier, Barber, Bridget E, Fidock, David A, Griffin, Paul, Lickliter, Jason and Chalon, Stephan (2024). Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study. The Lancet Infectious Diseases. doi: 10.1016/s1473-3099(24)00664-9

Safety, tolerability, pharmacokinetics, and antimalarial activity of MMV533: a phase 1a first-in-human, randomised, ascending dose and food effect study, and a phase 1b Plasmodium falciparum volunteer infection study

2024

Journal Article

QuantumEyes: towards better interpretability of quantum circuits

Ruan, Shaolun, Guan, Qiang, Griffin, Paul, Mao, Ying and Wang, Yong (2024). QuantumEyes: towards better interpretability of quantum circuits. IEEE Transactions on Visualization and Computer Graphics, 30 (9), 6321-6333. doi: 10.1109/tvcg.2023.3332999

QuantumEyes: towards better interpretability of quantum circuits

2024

Journal Article

Revolutionising RSV infection prevention and control Unveiling new options in the fight against RSV

Spence, Luke, Armstrong, Mark R. and Griffin, Paul M. (2024). Revolutionising RSV infection prevention and control Unveiling new options in the fight against RSV. Medicine Today, 25 (7), 45-54.

Revolutionising RSV infection prevention and control Unveiling new options in the fight against RSV

2024

Journal Article

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

Bennett, Chijioke, Woo, Wayne, Bloch, Mark, Cheung, King, Griffin, Paul (Novavax 2019nCoV-311 Study Group), Mohan, Rahul, Deshmukh, Sachin, Arya, Mark, Cumming, Oscar, Neville, A Munro, McCallum Pardey, Toni G, Plested, Joyce S, Cloney-Clark, Shane, Zhu, Mingzhu, Kalkeri, Raj, Patel, Nita, Marcheschi, Alex, Swan, Jennifer, Smith, Gale, Cho, Iksung, Glenn, Gregory M, Walker, Robert, Mallory, Raburn M, Anderson, Anna, Ang, Mary, Barnes, Timothy, Bassin, Michelle, Bessey, Kate, Bowler, Simon ... Novavax 2019nCoV-311 Study Group (2024). Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial. The Lancet Infectious Diseases, 24 (6), 581-593. doi: 10.1016/S1473-3099(24)00077-X

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial

2024

Journal Article

Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target

Sasso, Etianne Martini, Muraki, Katsuhiko, Eaton-Fitch, Natalie, Smith, Peter, Jeremijenko, Andrew, Griffin, Paul and Marshall-Gradisnik, Sonya (2024). Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target. Frontiers in Immunology, 15 1264702, 1-18. doi: 10.3389/fimmu.2024.1264702

Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target

2024

Journal Article

Bracing for impact Navigating the complexities of the 2024 influenza season in Australia

Spence, Luke, Armstrong, Mark R. and Griffin, Paul M. (2024). Bracing for impact Navigating the complexities of the 2024 influenza season in Australia. Medicine Today, 25 (5), 39-48.

Bracing for impact Navigating the complexities of the 2024 influenza season in Australia

2024

Journal Article

Seasonal vaccination: bracing for winter

Armstrong, Mark R., Spence, Luke and Griffin, Paul M. (2024). Seasonal vaccination: bracing for winter. Medicine Today, 25 (5), 12-18.

Seasonal vaccination: bracing for winter

2024

Journal Article

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

Plotnik, David, Sager, Jennifer E., Aryal, Madhukar, Fanget, Marie C., Peter, Alessia, Schmid, Michael A., Cebrik, Deborah, Mogalian, Erik, Boundy, Keith, Yeh, Wendy W., Griffin, Paul and Reyes, Maribel (2024). A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness. Antimicrobial Agents and Chemotherapy, 68 (4). doi: 10.1128/aac.01273-23

A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness

2023

Journal Article

Immunogenicity and safety of heterologous omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3 randomized clinical trial

Bennett, Chijioke, Rivers, E. Joy, Woo, Wayne, Bloch, Mark, Cheung, King, Griffin, Paul, Mohan, Rahul, Deshmukh, Sachin, Arya, Mark, Cumming, Oscar, Neville, A. Munro, Pardey, Toni McCallum, Plested, Joyce S., Cloney-Clark, Shane, Zhu, Mingzhu, Kalkeri, Raj, Patel, Nita, Buchanan, Agi, Marcheschi, Alex, Swan, Jennifer, Smith, Gale, Cho, Iksung, Glenn, Gregory M., Walker, Robert and Mallory, Raburn M. (2023). Immunogenicity and safety of heterologous omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3 randomized clinical trial. Journal of Infectious Diseases, 230 (1), e4-e16. doi: 10.1093/infdis/jiad508

Immunogenicity and safety of heterologous omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3 randomized clinical trial

2023

Journal Article

Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial

Chappell, Keith J., Mordant, Francesca L., Amarilla, Alberto A., Modhiran, Naphak, Liang, Benjamin, Li, Zheyi, Wijesundara, Danushka K., Lackenby, Julia A., Griffin, Paul, Bennet, Jillian K., Hensen, Luca, Zhang, Wuji, Nguyen, Thi H.O., Tran, Mai H., Tapley, Peter, Barnes, James, Reading, Patrick C., Kedzierska, Katherine, Ranasinghe, Charani, Subbarao, Kanta, Watterson, Daniel, Young, Paul R. and Munro, Trent P. (2023). Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial. eBioMedicine, 97 104842. doi: 10.1016/j.ebiom.2023.104842

Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial

2023

Journal Article

Strong CD4+T-cell responses to ancestral and variant spike proteins are established by NVX-CoV2373 severe acute respiratory syndrome Coronavirus 2 primary vaccination

Fries, Louis, Formica, Neil, Mallory, Raburn M, Zhou, Haixia, Plested, Joyce S, Kalkeri, Raj, Moldovan, Ioana, Patel, Nita, Albert, Gary, Robinson, Michelle, Cho, Iksung, Chau, Gordon, Dubovsky, Filip, Glenn, Gregory M, Adams, Mark, Arya, Mark, Athan, Eugene, Berger, Ira, Bradley, Paul, Glover, Richard, Griffin, Paul, Kim, Joshua, Kitchener, Scott, Klein, Terry, Leah, Amber, Lemech, Charlotte, Lickliter, Jason, Manning, Mary Beth, Napier-Flood, Fiona ... Turner, Mark (2023). Strong CD4+T-cell responses to ancestral and variant spike proteins are established by NVX-CoV2373 severe acute respiratory syndrome Coronavirus 2 primary vaccination. Journal of Infectious Diseases, 228 (6), 734-741. doi: 10.1093/infdis/jiad163

Strong CD4+T-cell responses to ancestral and variant spike proteins are established by NVX-CoV2373 severe acute respiratory syndrome Coronavirus 2 primary vaccination

2023

Journal Article

Barriers to optimal management of syphilis in pregnancy and congenital syphilis in south-east Queensland: a qualitative investigation

Fowler, James A., Warzywoda, Sarah, Nourse, Clare, Wu, Mandy, Britton, Sumudu, Rowling, Diane, Griffin, Paul, Lazarou, Mattea, Hamilton, Zoe and Dean, Judith A. (2023). Barriers to optimal management of syphilis in pregnancy and congenital syphilis in south-east Queensland: a qualitative investigation. Sexual Health, 20 (6), 506-513. doi: 10.1071/sh23119

Barriers to optimal management of syphilis in pregnancy and congenital syphilis in south-east Queensland: a qualitative investigation

2023

Journal Article

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

de Bruyn, Guy, Wang, Joyce, Purvis, Annie, Ruiz, Martin Sanchez, Adhikarla, Haritha, Alvi, Saad, Bonaparte, Matthew I., Brune, Daniel, Bueso, Agustin, Canter, Richard M., Ceregido, Maria Angeles, Deshmukh, Sachin, Diemert, David, Finn, Adam, Forrat, Remi, Fu, Bo, Gallais, Julie, Griffin, Paul, Grillet, Marie-Helene, Haney, Owen, Henderson, Jeffrey A., Koutsoukos, Marguerite, Launay, Odile, Torres, Federico Martinon, Masotti, Roger, Michael, Nelson L., Park, Juliana, Rivera-Medina, Doris Maribel, Romanyak, Natalya ... Davis, Yvonne (2023). Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study. eClinicalMedicine, 62 102109, 102109. doi: 10.1016/j.eclinm.2023.102109

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

2023

Journal Article

Syphilis in pregnancy: a qualitative investigation of healthcare provider perspectives on barriers to syphilis screening during pregnancy in south-east Queensland

Warzywoda, Sarah, Fowler, James A., Nourse, Clare, Wu, Mandy, Britton, Sumudu, Rowling, Diane, Griffin, Paul, Lazarou, Mattea, Hamilton, Zoe and Dean, Judith A. (2023). Syphilis in pregnancy: a qualitative investigation of healthcare provider perspectives on barriers to syphilis screening during pregnancy in south-east Queensland. Sexual Health, 20 (4), 330-338. doi: 10.1071/sh22193

Syphilis in pregnancy: a qualitative investigation of healthcare provider perspectives on barriers to syphilis screening during pregnancy in south-east Queensland

2023

Journal Article

Expanding the geographic boundaries of Melioidosis in Queensland, Australia

Gassiep, Ian, Grey, Victoria, Thean, Li Jun, Farquhar, Drew, Clark, Julia E., Ariotti, Lawrence, Graham, Rikki, Jennison, Amy V., Bergh, Haakon, Anuradha, Satyamurthy, Dyer, Wendy, James, Christian, Huang, Andrea, Putt, Elise, Pakeerathan, Veenaa, Griffin, Paul M. and Harris, Patrick N. A. (2023). Expanding the geographic boundaries of Melioidosis in Queensland, Australia. The American Journal of Tropical Medicine and Hygiene, 108 (6), 1215-1219. doi: 10.4269/ajtmh.23-0002

Expanding the geographic boundaries of Melioidosis in Queensland, Australia

2023

Journal Article

Longitudinal transitions in tobacco use in youth and young adults: a latent transition analysis of the population assessment of tobacco and health study from Wave 1 to 5

Huang, Siyi, Chen, Qiushi, Griffin, Paul, Liu, Guodong and Azagba, Sunday (2023). Longitudinal transitions in tobacco use in youth and young adults: a latent transition analysis of the population assessment of tobacco and health study from Wave 1 to 5. Addictive Behaviors, 138 107548, 1-9. doi: 10.1016/j.addbeh.2022.107548

Longitudinal transitions in tobacco use in youth and young adults: a latent transition analysis of the population assessment of tobacco and health study from Wave 1 to 5

2023

Journal Article

Improving care for patients with Clostridioides difficile infection: A clinical practice and healthcare systems perspective

Hocking, Lucy, Wilcox, Mark, Petrosillo, Nicola, Griffin, Paul, Steiner, Theodore, Attara, Gail, Doré, Joel, Cabling, Mark, Stockwell, Stephanie, Romanelli, Robert J. and Marjanovic, Sonja (2023). Improving care for patients with Clostridioides difficile infection: A clinical practice and healthcare systems perspective. Frontiers in Medicine, 9 1033417, 1-21. doi: 10.3389/fmed.2022.1033417

Improving care for patients with Clostridioides difficile infection: A clinical practice and healthcare systems perspective

2022

Journal Article

A multinational Delphi consensus to end the COVID-19 public health threat

Lazarus, Jeffrey V., Romero, Diana, Kopka, Christopher J., Karim, Salim Abdool, Abu-Raddad, Laith J., Almeida, Gisele, Baptista-Leite, Ricardo, Barocas, Joshua A., Barreto, Mauricio L., Bar-Yam, Yaneer, Bassat, Quique, Batista, Carolina, Bazilian, Morgan, Chiou, Shu-Ti, del Rio, Carlos, Dore, Gregory J., Gao, George F., Gostin, Lawrence O., Hellard, Margaret, Jimenez, Jose L., Kang, Gagandeep, Lee, Nancy, Matičič, Mojca, McKee, Martin, Nsanzimana, Sabin, Oliu-Barton, Miquel, Pradelski, Bary, Pyzik, Oksana, Rabin, Kenneth ... Øvrehus, Anne (2022). A multinational Delphi consensus to end the COVID-19 public health threat. Nature, 611 (7935), 332-345. doi: 10.1038/s41586-022-05398-2

A multinational Delphi consensus to end the COVID-19 public health threat

2022

Journal Article

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Mallory, Raburn M., Formica, Neil, Pfeiffer, Susan, Wilkinson, Bethanie, Marcheschi, Alex, Albert, Gary, McFall, Heather, Robinson, Michelle, Plested, Joyce S., Zhu, Mingzhu, Cloney-Clark, Shane, Zhou, Bin, Chau, Gordon, Robertson, Andreana, Maciejewski, Sonia, Hammond, Holly L., Baracco, Lauren, Logue, James, Frieman, Matthew B., Smith, Gale, Patel, Nita, Glenn, Gregory M., Adams, Mark, Arya, Mark, Athan, Eugene, Berger, Ira, Bradley, Paul, Briskin, Toby, Glover II, Richard ... Turner, Mark (2022). Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases, 22 (11), 1565-1576. doi: 10.1016/S1473-3099(22)00420-0

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

2022

Journal Article

Japanese encephalitis - a recent rise in Australian cases

Armstrong, Mark, Grey, Victoria and Griffin, Paul (2022). Japanese encephalitis - a recent rise in Australian cases. Medicine Today, 23 (8), 49-53.

Japanese encephalitis - a recent rise in Australian cases